The prospect of FKBP51 as a drug target

ChemMedChem. 2012 Aug;7(8):1351-9. doi: 10.1002/cmdc.201200137. Epub 2012 May 13.

Abstract

The FK506 binding protein 51 (FKBP51) is best known as an Hsp90-associated co-chaperone that regulates the responsiveness of steroid hormone receptors. In human genetic association studies, FKBP51 has repeatedly been associated with emotion processing and numerous stress-related affective disorders. It has also been implicated in contributing to the glucocorticoid hyposensitivity observed in New World primates. More recently, several research groups have consistently shown a protective effect of FKBP51 knockout or knockdown on stress endocrinology and stress-coping behavior in animal models of depression and anxiety. The principal druggability of FKBP51 is exemplified by the prototypic FKBP ligands FK506 and rapamycin. Moreover, FKBP51 is highly suited for X-ray co-crystallography, which should facilitate the rational drug design of improved FKBP51 ligands. In summary, FKBP51 has emerged as a promising new drug target for stress-related disorders that should be amenable to drug discovery.

MeSH terms

  • Animals
  • Antidepressive Agents / therapeutic use
  • Depressive Disorder / drug therapy
  • Depressive Disorder / metabolism
  • Drug Design
  • Energy Metabolism
  • Gene Knockdown Techniques
  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • Ligands
  • Mice
  • Mice, Knockout
  • Polymorphism, Single Nucleotide
  • Receptors, Steroid / metabolism
  • Tacrolimus Binding Proteins / antagonists & inhibitors*
  • Tacrolimus Binding Proteins / genetics
  • Tacrolimus Binding Proteins / metabolism

Substances

  • Antidepressive Agents
  • HSP90 Heat-Shock Proteins
  • Ligands
  • Receptors, Steroid
  • Tacrolimus Binding Proteins
  • tacrolimus binding protein 5